JP2014166186A5 - - Google Patents

Download PDF

Info

Publication number
JP2014166186A5
JP2014166186A5 JP2014095688A JP2014095688A JP2014166186A5 JP 2014166186 A5 JP2014166186 A5 JP 2014166186A5 JP 2014095688 A JP2014095688 A JP 2014095688A JP 2014095688 A JP2014095688 A JP 2014095688A JP 2014166186 A5 JP2014166186 A5 JP 2014166186A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
compound
carcinoma
binder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014095688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014166186A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014166186A publication Critical patent/JP2014166186A/ja
Publication of JP2014166186A5 publication Critical patent/JP2014166186A5/ja
Withdrawn legal-status Critical Current

Links

JP2014095688A 2006-06-30 2014-05-07 医薬目的のための新規な多官能性化合物 Withdrawn JP2014166186A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US80629806P 2006-06-30 2006-06-30
EP06013640.5 2006-06-30
EP06013641.3 2006-06-30
EP06013640 2006-06-30
EP06013641 2006-06-30
US60/806,298 2006-06-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009517014A Division JP2009541398A (ja) 2006-06-30 2007-07-02 医薬目的のための新規な多官能性化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016114025A Division JP2017002039A (ja) 2006-06-30 2016-06-08 医薬目的のための新規な多官能性化合物

Publications (2)

Publication Number Publication Date
JP2014166186A JP2014166186A (ja) 2014-09-11
JP2014166186A5 true JP2014166186A5 (cg-RX-API-DMAC7.html) 2015-05-07

Family

ID=38353353

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009517014A Pending JP2009541398A (ja) 2006-06-30 2007-07-02 医薬目的のための新規な多官能性化合物
JP2014095688A Withdrawn JP2014166186A (ja) 2006-06-30 2014-05-07 医薬目的のための新規な多官能性化合物
JP2016114025A Pending JP2017002039A (ja) 2006-06-30 2016-06-08 医薬目的のための新規な多官能性化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009517014A Pending JP2009541398A (ja) 2006-06-30 2007-07-02 医薬目的のための新規な多官能性化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016114025A Pending JP2017002039A (ja) 2006-06-30 2016-06-08 医薬目的のための新規な多官能性化合物

Country Status (5)

Country Link
US (1) US8470963B2 (cg-RX-API-DMAC7.html)
EP (3) EP3669894A3 (cg-RX-API-DMAC7.html)
JP (3) JP2009541398A (cg-RX-API-DMAC7.html)
CN (1) CN101528263B (cg-RX-API-DMAC7.html)
WO (1) WO2008000517A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092447A2 (en) * 2006-02-06 2007-08-16 Burnham Institute For Medical Research Methods and compositions related to targeting tumors and wounds
WO2008121354A1 (en) 2007-03-30 2008-10-09 Duke University A method of modulating the activity of a nucleic acid molecule
WO2010089019A1 (en) 2009-01-14 2010-08-12 Andre Koltermann Compounds comprising n-formyl-methionine residues and tumor-targeting peptides
IN2012DN02345A (cg-RX-API-DMAC7.html) * 2009-09-16 2015-08-21 Univ Duke
EP2828283B1 (en) * 2012-03-22 2018-04-18 The Curators Of The University Of Missouri Peptide with gold binding and egfr receptor affinity and same attached to gold nanostructure
US10066323B2 (en) 2014-04-16 2018-09-04 Duke University Electrospun cationic nanofibers and methods of making and using the same
GB201609083D0 (en) 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
US12447464B2 (en) 2016-12-22 2025-10-21 Duke University Polycationic microfibers and methods of using the same
JP7073487B2 (ja) * 2017-06-16 2022-05-23 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体
WO2020018941A1 (en) * 2018-07-19 2020-01-23 The Regents Of The University Of California Peptides for activation of cell signaling in osteoprogenitor cells
CN109055476B (zh) * 2018-08-07 2021-07-09 河南大学 一种生物活性肽p11在治疗甲状腺癌的药物中效果分析方法
CN109679981A (zh) * 2019-02-21 2019-04-26 武汉大学 一种甲酰基肽定向进化噬菌体及其制备方法与应用
CN111474370B (zh) * 2020-04-22 2021-04-06 天津医科大学总医院 检测甲酰肽或甲酰肽受体-1配体含量的方法及应用
US20240050582A1 (en) * 2021-03-08 2024-02-15 Universiteit Gent Conjugates including multiple saccharidic chains on a linear protein and uses in mammals feed
CN115448980A (zh) * 2021-06-08 2022-12-09 戴德森医疗财团法人嘉义基督教医院 表面链结标靶多肽的类病毒颗粒及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1055932A (en) 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
WO1993022343A1 (en) * 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
CA2223833C (en) 1995-06-07 2010-12-21 Nicholas C. Wrighton Compounds and peptides that bind to the erythropoietin receptor
DE19853778C1 (de) 1998-11-21 2000-09-21 Basf Ag DNA-Sequenzen kodierend einen Glutamat/Malat-Translokator, Plasmide Bakterien, Hefen und Pflanzen enthaltend diesen Transporter
AU2030000A (en) 1998-11-25 2000-06-13 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
US6017537A (en) * 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US20030099629A1 (en) * 1999-03-11 2003-05-29 Immunomedics, Inc. Recombinant onconase and chemical conjugates and fusion proteins of recombinant onconase
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
NZ522924A (en) 2000-05-26 2004-12-24 Ortho Mcneil Pharm Inc Neuroprotective peptides
CA2444637A1 (en) 2001-01-16 2002-07-18 Ramot University Authority For Applied Research & Industrial Development Ltd. Hybrid peptides for treatment of bacteremia and septicemia
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
AU2003245648A1 (en) * 2002-06-20 2004-01-06 University Of Maryland Biotechnology Institute Scaffolded maleimide clusters for multivalent peptide assembly
RU2329274C2 (ru) 2002-09-11 2008-07-20 Фрезениус Каби Дойчланд Гмбх Способ получения производных гидроксиалкилкрахмала
NZ543935A (en) 2003-05-12 2008-06-30 Affymax Inc Peptides that bind to the erythropoietin receptor
BRPI0411160A (pt) 2003-05-12 2006-07-11 Affymax Inc novos compostos modificados com poli(glicol etilênico) e usos dos mesmos
EA010015B1 (ru) 2003-05-12 2008-06-30 Афимакс, Инк. Новый разделительный фрагмент (спейсер) для модифицированных полиэтиленгликолем соединений на основе пептидов
AP2042A (en) 2003-05-12 2009-09-07 Affymax Inc Novel peptides that bind to the erythropoietin receptor
EP1538164A1 (en) * 2003-12-04 2005-06-08 Vectron Therapeutics AG RGD targeting moiety its production and use

Similar Documents

Publication Publication Date Title
JP2014166186A5 (cg-RX-API-DMAC7.html)
Gautam et al. Tumor homing peptides as molecular probes for cancer therapeutics, diagnostics and theranostics
Dubuisson et al. Antibodies and derivatives targeting DR4 and DR5 for cancer therapy
FI3348571T3 (fi) Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini
CA2807942C (en) Erythrocyte-binding therapeutics
JP2021502810A5 (cg-RX-API-DMAC7.html)
JP2014506135A5 (cg-RX-API-DMAC7.html)
JP2009505676A5 (cg-RX-API-DMAC7.html)
HRP20170879T1 (hr) Genetski proizvodi koji su diferencijalno izraženi u tumorima i njihova primjena
JP2016531583A5 (cg-RX-API-DMAC7.html)
WO2010027827A3 (en) Targeted costimulatory polypeptides and methods of use to treat cancer
HRP20150300T4 (hr) Novi i snažni mhc-razred ii peptidi derivirani iz survivina i neurokana
FI3283521T3 (fi) Lääkekonjugaatteja käsittäen vasta-aineita claudiinia 18.2 vastaan
JP2016187356A5 (cg-RX-API-DMAC7.html)
HRP20220553T1 (hr) Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela
JPWO2019246004A5 (cg-RX-API-DMAC7.html)
JP2010531140A5 (cg-RX-API-DMAC7.html)
JP2017506217A5 (cg-RX-API-DMAC7.html)
Davoodi et al. Internalizing RGD, a great motif for targeted peptide and protein delivery: a review article
WO2011008260A3 (en) Bifunctional stapled polypeptides and uses thereof
IN2014CN03936A (cg-RX-API-DMAC7.html)
HRP20230878T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raznih karcinoma (seq id 25 - mrax5-003)
JP2015506961A5 (cg-RX-API-DMAC7.html)
WO2008100482A3 (en) Peptides that target to tumor blood vessels of lung cancer and applications thereof
Ndong et al. Antibody-mediated targeting of iron oxide nanoparticles to the folate receptor alpha increases tumor cell association in vitro and in vivo